ADX‑629 : Aldeyra Therapeutics kicks off atopic dermatitis phase 2 trial
American biotech company Aldeyra Therapeutics said that it has enrolled the first patient in a phase 2 clinical trial of ADX‑629 for the treatment of atopic dermatitis. ADX‑629 is an orally administered RASP modulator. According to Aldeyra Therapeutics, the phase 2 trial will be held at multiple centers and will assess the efficacy and safety […]